Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
Standard
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. / Welslau, Manfred; Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Ettl, Johannes; Lüftner, Diana; Belleville, Erik; Schütz, Florian; Fasching, Peter A; Kolberg, Hans-Christian; Nabieva, Naiba; Overkamp, Friedrich; Taran, Florin-Andrei; Brucker, Sara Y; Wallwiener, Markus; Tesch, Hans; Schneeweiss, Andreas; Fehm, Tanja N.
in: GEBURTSH FRAUENHEILK, Jahrgang 79, Nr. 10, 10.2019, S. 1090-1099.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
AU - Welslau, Manfred
AU - Hartkopf, Andreas D
AU - Müller, Volkmar
AU - Wöckel, Achim
AU - Lux, Michael P
AU - Janni, Wolfgang
AU - Ettl, Johannes
AU - Lüftner, Diana
AU - Belleville, Erik
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Kolberg, Hans-Christian
AU - Nabieva, Naiba
AU - Overkamp, Friedrich
AU - Taran, Florin-Andrei
AU - Brucker, Sara Y
AU - Wallwiener, Markus
AU - Tesch, Hans
AU - Schneeweiss, Andreas
AU - Fehm, Tanja N
PY - 2019/10
Y1 - 2019/10
N2 - Significant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being developed (e.g. margetuximab, DS-8201a, pyrotinib) which can overcome other resistance mechanisms in the HER2 signalling pathway. In the field of hormone-receptor-positive breast cancer, an mTOR inhibitor and CDK4/6 inhibitors were introduced in the past. Now the introduction of the first PI3K inhibitor is forthcoming and this inhibitor will involve genetic testing of the tumour for a mutation in the PIK3CA gene. There are also significant advancements in triple-negative breast cancer: By combining chemotherapy and immunotherapy, an advantage for overall survival was able to be demonstrated in a subgroup (immune cells PD-L1-positive). The PARP inhibitor therapy for HER2-negative patients with a germ line mutation in BRCA1 or BRCA2 was also associated with an improved overall survival in a subgroup. These promising new study results are summarised in this review.
AB - Significant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being developed (e.g. margetuximab, DS-8201a, pyrotinib) which can overcome other resistance mechanisms in the HER2 signalling pathway. In the field of hormone-receptor-positive breast cancer, an mTOR inhibitor and CDK4/6 inhibitors were introduced in the past. Now the introduction of the first PI3K inhibitor is forthcoming and this inhibitor will involve genetic testing of the tumour for a mutation in the PIK3CA gene. There are also significant advancements in triple-negative breast cancer: By combining chemotherapy and immunotherapy, an advantage for overall survival was able to be demonstrated in a subgroup (immune cells PD-L1-positive). The PARP inhibitor therapy for HER2-negative patients with a germ line mutation in BRCA1 or BRCA2 was also associated with an improved overall survival in a subgroup. These promising new study results are summarised in this review.
U2 - 10.1055/a-1001-9952
DO - 10.1055/a-1001-9952
M3 - SCORING: Journal article
C2 - 31656319
VL - 79
SP - 1090
EP - 1099
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 10
ER -
